Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 12/20 | 1.00 |
| ▸ | TGM2 | P21980 | 1/20 | 0.70 |
| ▸ | NT5E | P21589 | 1/20 | 0.63 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.63 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.60 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.60 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.60 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.59 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16144169 | 0.97 | KRAS (0.94) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL22268205 | 0.94 | KRAS (0.89) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL17532544 | 0.93 | KRAS (0.86) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL17539279 | 0.92 | KRAS (0.85) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL16112811 | 0.91 | KRAS (0.86) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL16112808 | 0.91 | KRAS (0.86) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL16113020 | 0.90 | KRAS (1.00) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL16113018 | 0.90 | KRAS (1.00) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL16113628 | 0.90 | KRAS (1.00) | KRASTGM2NT5EFUT5P2RY2 | |
| SCHEMBL17539263 | 0.89 | KRAS (0.88) | KRASTGM2NT5EFUT5P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723753-B2 | Ras inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, RASGRP1 | KRAS 1/4885TGM2 3081/4885NT5E 2879/4885 |
| US-10723753-B2 | Ras inhibitors and uses thereof | KRAS, NRAS, RASGRP1 | KRAS 1/4885TGM2 3081/4885NT5E 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.